The results of the advisory council of experts «Place of calcimimetics in modern clinical recommendations for mbd-ckd – in the light of new studies using cincalcet»

A.Yu. Zemchenkov

1 SBHCI "Sity Mariinsky Hospital " - City Nephrological Center, St. Petersburg; 2 Northwestern Medical University n.a. I.I. Mechnikov, Department of Internal Diseases and Nephrology
March 5, 2014, an Advisory Board meeting «The Role of Calcimimetics in Current Clinical Guidelines for CKD – MBD in the Light of New Research Findings» was held in Moscow at the initiative of the Russian Dialysis Society.
The Board was convened on the eve of preparation of updates to the Russian national recommendations for mineral and bone disorders in chronic kidney disease (CKD-MBD), created and published by the Russian Dialysis Society (RDS) in 2011 after publication of clinical guidelines for the diagnosis, evaluation, prevention and treatment
of CKD–MBD, KDIGO 2009. Upon new clinical studies findings discussion, the experts signed the resolution.

About the Autors

Zemchenkov A.Yu. - Head of the Dialysis Department St. Petersburg SBHCI "Sity Mariinsky Hospital", Associate Professor at the Department of Internal Diseases and Nephrology Northwest Medical University n.a. I.I. Mechnikov

Similar Articles

Бионика Медиа